Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung.
Baird K, Glod J, Steinberg SM, Reinke D, Pressey JG, Mascarenhas L, Federman N, Marina N, Chawla S, Lagmay JP, Goldberg J, Milhem M, Loeb DM, Butrynski JE, Turpin B, Staddon A, Spunt SL, Jones RL, Rodler ET, Schuetze SM, Okuno SH, Helman L.
Baird K, et al. Among authors: butrynski je.
Sarcoma. 2020 Apr 30;2020:7935475. doi: 10.1155/2020/7935475. eCollection 2020.
Sarcoma. 2020.
PMID: 32398945
Free PMC article.